{"ticker": {"uuid": "5d0f907b-76f7-4e1d-8feb-9b9eaa03c361", "symbol": "ERNA", "name": "Eterna Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Ernexa Therapeutics announces 1-for-25 reverse stock split; shares down", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AJBVV95cUxNeWUxX2dGbDlXNjFiSzU3b0F0R2VXSHpaQ25hQzYwOVdIajNHVVFCeFY5X3p0c2cxMDB2NGRtZG9wdXFJLUZ6dFV0YlMtOGF0VGh1SlNJX2MtMXJETFlndzdJbjl5RmN1WFRtNEl5S0JMdm5YckRBRkpKZkZGdzVheTZTeUVnbE1TWjE0VmczTFNBWmtlUVdFWklKS1hfWHFaSkNZWVNYN2l5VzVqcW42bkRlaEE0TGJVSHVsVi1zU3NPLThmam9SdzFGcWlMNkVLVlJ5cGxOcnV2VllhSklhUUo2QWtIMmJhbEhOeUREMWVUdkVNenkybVR1NGhLWTFtU2hER081LTU5Tzc1Rl9Sdmp0SHVKV0kzZFVPNnF5SUZCVVVLZk5BWHZNZ1RLSmo3ejhYWTJiOU9TaDZoWWhnam9PQTVKLUV5M0prNm1RUEM?oc=5", "source_name": "MSN", "published_at": "2026-07-18T00:28:45+00:00", "published_display": "18 Jul 2026 00:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy", "summary": "Ernexa Therapeutics Inc. (NASDAQ: ERNA) saw its stock climb after an independent preclinical study confirmed the anti-tumor activity of its lead cell therapy candidate, ERNA-101, when combined with PD-1 checkpoint inhibition. This study reproduced earlier findings, showing comple", "url": "https://www.sahmcapital.com/news/content/ernexa-therapeutics-stock-climbs-after-independent-study-validates-erna-101-tumor-fighting-cell-therapy-2026-07-15", "source_name": "Sahm", "published_at": "2026-07-17T06:10:59", "published_display": "17 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to book forward of Ernexa Therapeutics Inc. \u2013 NASDAQ:ERNAW", "summary": "This article provides a brief mention of the \"Price to book forward\" for Ernexa Therapeutics Inc. (NASDAQ: ERNAW). It appears to be a financial data point from TradingView, indicating that the market for this stock is currently closed with no trades. The content is very minimal, ", "url": "https://www.tradingview.com/symbols/NASDAQ-ERNAW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-16T11:42:48", "published_display": "16 Jul 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERNA Stock Draws Trader Attention As Biotech Maps 2026\u20132027 Trial Roadmap", "summary": "Ernexa Therapeutics Inc. (ERNA) stock surged by 45.05% due to promising clinical trial developments for its ERNA-101 cell therapy. The company plans to file an IND for ERNA-101 in Q3 2026, begin a Phase 1 trial in Q4 2026 for platinum-resistant ovarian cancer, and expects initial", "url": "https://timothysykes.com/news/ernexa-therapeutics-inc-erna-news-2026_07_15/", "source_name": "timothysykes.com", "published_at": "2026-07-15T16:42:48", "published_display": "15 Jul 2026 16:42", "sentiment": "positive", "sentiment_pct": 80, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Says Preclinical Data Shows Anti-Tumor Activity of ERNA-101 Combination", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-says-preclinical-data-130120590.html", "source_name": "MT Newswires", "published_at": "2026-07-15T13:01:20+00:00", "published_display": "15 Jul 2026 13:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)", "summary": "Ernexa Therapeutics (ERNA) shares soared 30% after an independent preclinical study validated its lead cell therapy candidate, ERNA-101, for ovarian cancer. The study, which replicated earlier findings, showed complete tumor clearance and extended survival in 67% of treated anima", "url": "https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-shares-soar-30-134330741.html", "source_name": "Market source", "published_at": "2026-07-15T13:13:32", "published_display": "15 Jul 2026 13:13", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Reports Independent Preclinical Validation of ERNA-101 Combination Therapy Ahead of Planned IND Submission", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxPd3RKUVdfblMtMEI3Mm1JaVNIaEV0UXdVR1I1TUdlcTJ6ZFktX0FDd1pEQ3ZndnFrWFVxTDNyNzhuQ2g0SU9JeXdtWTFyUVJCOWlYdzFiSXZBeElreTRpVmNVcEpldlowWG1JVTUzRDV6WXJuU2VYZnZiSHljVm91RHVXb1QxcEtwa1JHbG4zQ1lSd0h4dzd6SGlWSnVWRWJHSlh0Q1k1OGttSWktQ1dUVWFOdUtKNkZFX09kcnRFNTJKZUxLb0ZieTFTRXo4QnJOSEhfWWlaTTZaVVg5ZkhVZG9FcHhSWGRfbTFHaGF5dmI?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T12:00:00+00:00", "published_display": "15 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics stock surges 30% on preclinical data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNMXFPYUNBUUZsM0FFeENzSUtERDI3QWh2YUkzdjBSQ0FnMmd2NTFvVWhfX0hGaFFJQjdxcTRpbDk0bUZnUmhaMnU1SHR0ZEJNLVNFdjlkSHVsa3VHNjhBbDI0akpjTDZLeW9NWF9mVkZxTTNoZ291bTJNbGtnZnBKbVEtTUVKSWtBSGVQOWtnN0NXY2xuaWxYdXlmY05JdWMzTElJbmN6WllHQzRaMWlTVnRTRDUxd3Zz?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T11:56:57+00:00", "published_display": "15 Jul 2026 11:56", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry", "summary": "Ernexa Therapeutics announced independent validation of its lead cell therapy candidate, ERNA-101, showing complete tumor clearance and durable survival in ovarian cancer models when combined with anti-PD-1 therapy. This preclinical data, which reproduced earlier findings in a la", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327620/0/en/ernexa-therapeutics-receives-independent-validation-of-erna-101-with-complete-tumor-clearance-and-durable-survival-in-ovarian-cancer-models-ahead-of-planned-clinical-entry.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T12:13:32", "published_display": "15 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Wednesday's Pre-Market Session", "summary": "This article lists several healthcare stocks that are experiencing significant movement in Wednesday's pre-market session. It highlights both gainers, such as Ernexa Therapeutics and Catheter Precision, and losers, including Cardiff Oncology and NextCure, detailing their percenta", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60465595/12-health-care-stocks-moving-wednesday-s-pre-market-session", "source_name": "Benzinga", "published_at": "2026-07-15T12:13:32", "published_display": "15 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics (ERNA) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFBkZ3RVdTlfRXEzbE5ZQ244cEVmR0huaGluWVFaR21pdzl2OFNZQWxUMF92VERMbXJxNlIxaGJVd0ltQXh5VTlJbjJqc2hCUkVnY1B3LXc2cHBqakt1dnBuYk1qYVR4QmRC?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026", "summary": "Ernexa Therapeutics released a new \"CEO Corner\" featuring CEO Sanjeev Luther discussing the company's lead cell therapy candidate, ERNA-101, for advanced ovarian cancer. The video highlights ERNA-101's potential to transform immunologically \"cold\" tumors into those the immune sys", "url": "https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-ceo-corner-highlights-130100722.html", "source_name": "Market source", "published_at": "2026-07-14T13:17:54", "published_display": "14 Jul 2026 13:17", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Preclinical ovarian models: Ernexa's ERNA-101 cleared tumors with PD-1 blockade", "summary": "Ernexa Therapeutics released a CEO Corner video highlighting preclinical data for ERNA-101, its lead therapy candidate for platinum-resistant ovarian cancer. The video showcased complete tumor clearance and 100% long-term survival in ovarian cancer models when ERNA-101 was combin", "url": "https://www.stocktitan.net/news/ERNA/ernexa-therapeutics-ceo-corner-highlights-differentiated-erna-101-y3zud567hg2a.html", "source_name": "Stock Titan", "published_at": "2026-07-14T13:17:54", "published_display": "14 Jul 2026 13:17", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eterna Therapeutics (ERNA) Revenue Breakdown - Main Composition", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T16:33:26+00:00", "published_display": "13 Jul 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eterna Therapeutics (ERNA) News Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygJBVV95cUxPVlZLLVgwQjRPOWlCcExhLXhlT1ZscFVOd19RVHdFS3FJZWpTS2pOaWRBR0pxSlBQLTdsYmVyZFRiMERSMlUtcGRhR0F3MkN6cVNuYTAxSzQ3SnpDWXF2WmFiWEl3dG1EZnl6akk1NkhnckFRNG95WUZLOHZldmRPRHdVbUx1Z2FYRDJNQV9LdU1RU1dUb0FubFAwdTRuWEVPNjh0eDhVeWNOWlZ0WHZtRXZ2RDRId1IxY3lGRGZmNHNEQU1BMWE0dDFhb2lZVnNXd1VySEEzT3hoWU1ZN0ptek9oMGJfejRnZ01QeHJVeDFEalFDZms3aUxuaExyTDZaM29MUnZHbll5ZDdEczZMVXFLMzBWa19GOGF1NEVxaTF5N3MyaWZhaGZLN29DODgwOExHd2hPSzhqa3pXZGRXYl9xS0RfNlVCWEE?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T16:18:24+00:00", "published_display": "13 Jul 2026 16:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eterna Therapeutics(ERNA) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wJBVV95cUxQV1Jja01mRFJXMXRxcG1yN2FlNmpVajloNWtsME1Obkd1SGRoM0ZlNlctZWZwdEtOaVpPWVdiM3RBVUFSTGFFbkJkV3UyMG4zVnVSSUN2THM5aDdCaTAxOW1Bb25CcTF3S2Z6UmpCa2pfSTNQaUZPMmRvenpZZ3VrSzN6clFQNmtYaTR0VkdCMFdQdGd0RWpreEFPRHc0eDduNnlWN053RDdMR3hNNWFwZzlvbVVzVmY5b1hZNm9PYjZHS2xuWURTb1JMVHo3ZkpSR2oxVzNUNkR4aExQdGs3UlVqRUVtQ0k4UjZDMVFzNFdyUzVmOHZfTjFEUkYyaUI2WU1tVmtHcVI4UjU0QVhpaTBTSXRzMHh2MjFvNkoyXzE1MDNndjBhQkFVb0x1MTI1UUw5VTl4RFBHMlB5T2gyQ3ozSEZIS2N3bk9xeHhNTThuMTlzTG0tT24yMVV1Qmo3elVUV21ERDRfQ00?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T16:01:27+00:00", "published_display": "13 Jul 2026 16:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eterna Therapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T14:27:07+00:00", "published_display": "13 Jul 2026 14:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Updated July 2026 investor presentation from Ernexa Therapeutics (NASDAQ: ERNA)", "summary": "Ernexa Therapeutics Inc. (NASDAQ: ERNA) has furnished an updated investor presentation for July 2026 as part of a current report on Form 8-K. This updated presentation, which refreshes materials from February 2026, is available as Exhibit 99.1 and on the company's investor relati", "url": "https://www.stocktitan.net/sec-filings/ERNA/8-k-ernexa-therapeutics-inc-reports-material-event-b90adf079c3f.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:12:10", "published_display": "02 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics (ERNA) investors back directors, auditor and 2026 equity plan", "summary": "Ernexa Therapeutics Inc. (ERNA) shareholders approved the election of five directors, ratified Haskell & White LLP as the independent auditor for the 2026 fiscal year, and adopted the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan. These decisions were made at the 20", "url": "https://www.stocktitan.net/sec-filings/ERNA/8-k-ernexa-therapeutics-inc-reports-material-event-711940a5d9b3.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:12:10", "published_display": "02 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Ernexa Therapeutics Inc. \u2013 BOATS:ERNAW", "summary": "The article discusses the price to sales forward metric for Ernexa Therapeutics Inc. (ERNAW). It appears to be a financial data page from TradingView, indicating that the market is closed and no trades have occurred for this specific metric.", "url": "https://www.tradingview.com/symbols/BOATS-ERNAW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:39:33", "published_display": "28 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Ernexa Therapeutics Inc. \u2013 BOATS:ERNAW", "summary": "This article focuses on the \"Price to earnings forward\" metric for Ernexa Therapeutics Inc. (BOATS:ERNAW) as presented on TradingView. It appears to be a financial data snippet rather than a detailed analysis, indicating that there is no current trading activity or value for this", "url": "https://www.tradingview.com/symbols/BOATS-ERNAW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:11:15", "published_display": "28 Jun 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics (ERNA) finance SVP resigns, will aid transition", "summary": "Ernexa Therapeutics Inc. announced the resignation of its Senior Vice President of Finance, Sandra Gurrola, effective July 3, 2026. Her resignation is not due to any disagreements with the company's operations or policies. Ms. Gurrola will provide part-time transition assistance ", "url": "https://www.stocktitan.net/sec-filings/ERNA/8-k-ernexa-therapeutics-inc-reports-material-event-fd208f426337.html", "source_name": "Stock Titan", "published_at": "2026-06-26T22:39:33", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sandra Gurrola to Resign as Ernexa's Senior VP of Finance, Effective July 3, 2026", "summary": "Ernexa Therapeutics announced that Sandra Gurrola, Senior Vice President of Finance, will resign effective July 3, 2026. She will provide limited transition support and her departure is not due to disagreements with the company. Ernexa has initiated a search for her replacement.", "url": "https://www.tradingview.com/news/tradingview:f1926ad3928a9:0-sandra-gurrola-to-resign-as-ernexa-s-senior-vp-of-finance-effective-july-3-2026/", "source_name": "TradingView", "published_at": "2026-06-26T20:33:17", "published_display": "26 Jun 2026 20:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Inc. Announces Resignation of Sandra Gurrola from Senior Vice President of Finance, Effective July 3, 2026", "summary": "Ernexa Therapeutics Inc. announced that Sandra Gurrola, Senior Vice President of Finance, has resigned, with her resignation becoming effective on July 3, 2026. Her departure is not due to any disagreements with the company. Ms. Gurrola will provide part-time transition assistanc", "url": "https://www.marketscreener.com/news/ernexa-therapeutics-inc-announces-resignation-of-sandra-gurrola-from-senior-vice-president-of-finan-ce7f5edadd8cfe22", "source_name": "www.marketscreener.com", "published_at": "2026-06-26T04:30:00", "published_display": "26 Jun 2026 04:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa uses video to explain its cell-therapy strategy and patient mission", "summary": "Ernexa Therapeutics has launched a \"CEO Corner\" video platform featuring CEO Sanjeev Luther to provide deeper insights into the company's progress, scientific strategy, and vision for cell therapies targeting advanced cancer and autoimmune diseases. The inaugural video outlines E", "url": "https://www.stocktitan.net/news/ERNA/ernexa-therapeutics-launches-ceo-corner-to-provide-deeper-insights-uvg0jwk9ersq.html", "source_name": "Stock Titan", "published_at": "2026-06-25T22:10:29", "published_display": "25 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-launches-ceo-corner-131500811.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T13:15:00+00:00", "published_display": "25 Jun 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Launches CEO Corner to Provide Deeper Accessibility", "summary": "Ernexa Therapeutics has launched its new \"CEO Corner\" platform featuring CEO Sanjeev Luther. This initiative aims to provide stakeholders with deeper insights into the company's progress, scientific strategy, and vision for developing innovative, scalable, and affordable cell the", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317625/0/en/ernexa-therapeutics-launches-ceo-corner-to-provide-deeper-insights-into-company-progress-scientific-strategy-and-vision-for-patients.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T13:42:11", "published_display": "25 Jun 2026 13:42", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study", "summary": "Ernexa Therapeutics is on track to become a clinical-stage biotechnology company with its lead oncology candidate, ERNA-101, slated for a Q3 2026 IND submission and a Q4 2026 first-in-human Phase 1 clinical study. The company has made significant progress in manufacturing and reg", "url": "https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-positioned-become-clinical-124700325.html", "source_name": "Market source", "published_at": "2026-06-19T09:09:52", "published_display": "19 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERNA Should I Buy", "summary": "An Intellectia AI analysis suggests that Ernexa Therapeutics Inc (ERNA) is not a strong buy for long-term beginner investors despite a favorable analyst price target of $30. The company shows potential with innovative immune-oncology approaches and clinical trial advancements for", "url": "https://intellectia.ai/en/stock/ERNA/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-06-19T07:11:25", "published_display": "19 Jun 2026 07:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Says Investigational New Drug Submission for ERNA-101 on Track for Q3", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-says-investigational-drug-131905563.html", "source_name": "MT Newswires", "published_at": "2026-06-17T13:19:05+00:00", "published_display": "17 Jun 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa sees ERNA-101 enter first-in-human study in Q4 2026", "summary": "Ernexa Therapeutics (Nasdaq: ERNA) announced significant progress for its lead oncology candidate, ERNA-101, targeting an Investigational New Drug (IND) submission in Q3 2026 and a first-in-human Phase 1 study by Q4 2026. Preclinical data for ERNA-101 combined with PD-1 blockade ", "url": "https://www.stocktitan.net/news/ERNA/ernexa-therapeutics-positioned-to-become-a-clinical-stage-2xaw657p971a.html", "source_name": "Stock Titan", "published_at": "2026-06-17T08:47:00", "published_display": "17 Jun 2026 08:47", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Advances ERNA-101 Towards First-in-Human Trials as Manufacturing and Regulatory Milestones are Achieved | ERNA Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxPVmJBR3JweEhoTHNBUkY4WEJlY1RVOTd0VGNKUUtkQ3hSczJSZHZmVkdhd3VoSnUyb2ZqRHN1bFR6ZUxxUjVLc2hSWTRWaXNkQWVKLTFYNjdIU3k3Qngwb0FJUVlKdzJQc3VJWkFFNG44WVZJQkZMRnRqMTZvdGdnUVRTbzZfWDlveDlHNXRQSHUwMVdxSDlJMlVyWU5NaGxpQ2MwWFZPRktJekhqMnJnaVpxc01yS3FFMmRWQUJ1cFFJTG92VDBYR3k0SVRGVjE3RDlKcG5CVTduMHhWYi1MdzBvOWhOd1gzLUJ2WA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Ernexa Therapeutics Inc. \u2013 NASDAQ:ERNAW", "summary": "This article provides limited information on the number of shareholders for Ernexa Therapeutics Inc. (NASDAQ: ERNAW). It appears to be a stub or a placeholder from TradingView's financial data section, indicating that specific shareholder figures are not immediately presented in ", "url": "https://www.tradingview.com/symbols/NASDAQ-ERNAW/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-12T05:10:28", "published_display": "12 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer", "summary": "Ernexa Therapeutics discussed the significant unmet need in ovarian cancer and the potential of their ERNA-101 program during a Virtual Investor KOL Connect segment featuring Dr. Ira Winer. The discussion highlighted ERNA-101's dual mechanism, off-the-shelf scalability, and poten", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ernexa-therapeutics-highlights-ovarian-cancer-124100377.html", "source_name": "Market source", "published_at": "2026-06-10T03:09:56", "published_display": "10 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need,", "summary": "Ernexa Therapeutics recently participated in a Virtual Investor KOL Connect segment, where Dr. Ira Winer discussed the significant unmet need in ovarian cancer and the challenges of treating immunologically \"cold\" tumors. The discussion highlighted Ernexa's ERNA-101 program and i", "url": "https://www.globenewswire.com/news-release/2026/06/09/3308857/0/en/ernexa-therapeutics-highlights-ovarian-cancer-unmet-need-hope-for-patients-and-potential-accessibility-advantages-of-erna-101-in-virtual-investor-kol-connect-segment-featuring-dr-i.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T08:41:00", "published_display": "09 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERNA Stock News Today | Earnings, Events & Price Alerts", "summary": "This article provides recent news and events related to ERNA (Ernexa Therapeutics), including updates on its ovarian cancer treatment ERNA-101 and its planned IND submission. Key news highlights involve significant loss narrowing, positive therapy results, and a recent 1-for-25 r", "url": "https://intellectia.ai/en/stock/ERNA/news", "source_name": "Intellectia AI", "published_at": "2026-06-03T09:39:45", "published_display": "03 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa readies ERNA-101 experimental therapy for first human tests, IND Q3 2026", "summary": "Ernexa Therapeutics announced significant progress for its lead therapeutic candidate, ERNA-101, by completing manufacturing milestones including process development and transitioning to GMP manufacturing. These achievements position the company for a planned Investigational New ", "url": "https://www.stocktitan.net/news/ERNA/ernexa-therapeutics-successfully-completes-key-manufacturing-and-ind-ruev4vav4hrx.html", "source_name": "Stock Titan", "published_at": "2026-05-28T09:10:39", "published_display": "28 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ernexa-therapeutics-successfully-completes-key-121100351.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T12:11:00+00:00", "published_display": "27 May 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ernexa Stock Is Jumping Today: What's Going On? - Ernexa Therapeutics (NASDAQ:ERNA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQZy1pRDdiSHMxVDBhb0Vfb01NMnFDbHYwT180UmliQUo5Nl9CSmFSU3k3U1lwMzVtR3RodXlFUU40Y2RCc0VVZ0xoR0xENzY3a1VkR2k0bDBvNWtOR0dQSUNCOHFkbVhLa2hla1hIdVJXdklueVVpdmtuN0J5X1lhT3ZKajQ3a1phWHJSLU9FNFByOGNqd0VLY29SOVJJdVc4dEhGZW1YVHA?oc=5", "source_name": "Benzinga", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQV1h5U2QwczdGX2hXRmVKS3FzRTY0ZThRZkRiLXhxWFRsLUZJLU4xY2xfWGk0WjRFUkY3OU5YYW1URDZ4eEpfeXoxS1F3RGhicFZEeVdzczlncjRvUFV2TWhzOFNTRXFWd1ZwQXYxUWY2SWtPUGJCSGpSc2pNNndURDRZamZZMlBCNUZBSTBZSVU0NmhUOExMWkVzSmJOSXpCeXlIaENPUDFQUWhKdG1vNkgtelYzUlVHa1RTQ2Z3?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Eterna Therapeutics Reports Promising Preclinical Results for ERNA-101 in Ovarian Cancer Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNRjJYNkt0ak9tUXNqT181S1dLRlFzbU5qR1YtZGdPdHhsSVNZQnZWTGdVOFJhUXNVWnhsN2RUSE53VTBMbXo1azBrUlVBajhQNExySV9SMDAyUXdGd1RCSmJ2QWZPcmF3ZTJzX0lvWkZ6QTFoUVFOalNvZzdVZ0lybWJKcldWZVpiRjhZMnV5aTBQeWlkTm95MzA5OWZkU0M4U1FITlpWN1RYUXJFdU9xWlNrNTBJTHlyQmRRZnRwTXF4LVdxY09zUTRrQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-01-14T08:00:00+00:00", "published_display": "14 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics (ERNA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5OQmc0V1paTHdReEFvVFpGdDlCVXJoSTl2MkQ0V0tuakNTX3BmazBqdXlQMDU1VVlsMVlSUkczVE82aTlWSEJpbmZHX1NXenp0WjktWUR6WGVYQQ?oc=5", "source_name": "MarketBeat", "published_at": "2022-10-20T11:01:36+00:00", "published_display": "20 Oct 2022 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Ernexa Therapeutics announces 1-for-25 reverse stock split; shares down", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AJBVV95cUxNeWUxX2dGbDlXNjFiSzU3b0F0R2VXSHpaQ25hQzYwOVdIajNHVVFCeFY5X3p0c2cxMDB2NGRtZG9wdXFJLUZ6dFV0YlMtOGF0VGh1SlNJX2MtMXJETFlndzdJbjl5RmN1WFRtNEl5S0JMdm5YckRBRkpKZkZGdzVheTZTeUVnbE1TWjE0VmczTFNBWmtlUVdFWklKS1hfWHFaSkNZWVNYN2l5VzVqcW42bkRlaEE0TGJVSHVsVi1zU3NPLThmam9SdzFGcWlMNkVLVlJ5cGxOcnV2VllhSklhUUo2QWtIMmJhbEhOeUREMWVUdkVNenkybVR1NGhLWTFtU2hER081LTU5Tzc1Rl9Sdmp0SHVKV0kzZFVPNnF5SUZCVVVLZk5BWHZNZ1RLSmo3ejhYWTJiOU9TaDZoWWhnam9PQTVKLUV5M0prNm1RUEM?oc=5", "source_name": "MSN", "published_at": "2026-07-18T00:28:45+00:00", "published_display": "18 Jul 2026 00:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy", "summary": "Ernexa Therapeutics Inc. (NASDAQ: ERNA) saw its stock climb after an independent preclinical study confirmed the anti-tumor activity of its lead cell therapy candidate, ERNA-101, when combined with PD-1 checkpoint inhibition. This study reproduced earlier findings, showing comple", "url": "https://www.sahmcapital.com/news/content/ernexa-therapeutics-stock-climbs-after-independent-study-validates-erna-101-tumor-fighting-cell-therapy-2026-07-15", "source_name": "Sahm", "published_at": "2026-07-17T06:10:59", "published_display": "17 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Ernexa Therapeutics Inc. \u2013 NASDAQ:ERNAW", "summary": "This article provides a brief mention of the \"Price to book forward\" for Ernexa Therapeutics Inc. (NASDAQ: ERNAW). It appears to be a financial data point from TradingView, indicating that the market for this stock is currently closed with no trades. The content is very minimal, ", "url": "https://www.tradingview.com/symbols/NASDAQ-ERNAW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-16T11:42:48", "published_display": "16 Jul 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERNA Stock Draws Trader Attention As Biotech Maps 2026\u20132027 Trial Roadmap", "summary": "Ernexa Therapeutics Inc. (ERNA) stock surged by 45.05% due to promising clinical trial developments for its ERNA-101 cell therapy. The company plans to file an IND for ERNA-101 in Q3 2026, begin a Phase 1 trial in Q4 2026 for platinum-resistant ovarian cancer, and expects initial", "url": "https://timothysykes.com/news/ernexa-therapeutics-inc-erna-news-2026_07_15/", "source_name": "timothysykes.com", "published_at": "2026-07-15T16:42:48", "published_display": "15 Jul 2026 16:42", "sentiment": "positive", "sentiment_pct": 80, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Says Preclinical Data Shows Anti-Tumor Activity of ERNA-101 Combination", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-says-preclinical-data-130120590.html", "source_name": "MT Newswires", "published_at": "2026-07-15T13:01:20+00:00", "published_display": "15 Jul 2026 13:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)", "summary": "Ernexa Therapeutics (ERNA) shares soared 30% after an independent preclinical study validated its lead cell therapy candidate, ERNA-101, for ovarian cancer. The study, which replicated earlier findings, showed complete tumor clearance and extended survival in 67% of treated anima", "url": "https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-shares-soar-30-134330741.html", "source_name": "Market source", "published_at": "2026-07-15T13:13:32", "published_display": "15 Jul 2026 13:13", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Reports Independent Preclinical Validation of ERNA-101 Combination Therapy Ahead of Planned IND Submission", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxPd3RKUVdfblMtMEI3Mm1JaVNIaEV0UXdVR1I1TUdlcTJ6ZFktX0FDd1pEQ3ZndnFrWFVxTDNyNzhuQ2g0SU9JeXdtWTFyUVJCOWlYdzFiSXZBeElreTRpVmNVcEpldlowWG1JVTUzRDV6WXJuU2VYZnZiSHljVm91RHVXb1QxcEtwa1JHbG4zQ1lSd0h4dzd6SGlWSnVWRWJHSlh0Q1k1OGttSWktQ1dUVWFOdUtKNkZFX09kcnRFNTJKZUxLb0ZieTFTRXo4QnJOSEhfWWlaTTZaVVg5ZkhVZG9FcHhSWGRfbTFHaGF5dmI?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T12:00:00+00:00", "published_display": "15 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics stock surges 30% on preclinical data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNMXFPYUNBUUZsM0FFeENzSUtERDI3QWh2YUkzdjBSQ0FnMmd2NTFvVWhfX0hGaFFJQjdxcTRpbDk0bUZnUmhaMnU1SHR0ZEJNLVNFdjlkSHVsa3VHNjhBbDI0akpjTDZLeW9NWF9mVkZxTTNoZ291bTJNbGtnZnBKbVEtTUVKSWtBSGVQOWtnN0NXY2xuaWxYdXlmY05JdWMzTElJbmN6WllHQzRaMWlTVnRTRDUxd3Zz?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T11:56:57+00:00", "published_display": "15 Jul 2026 11:56", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry", "summary": "Ernexa Therapeutics announced independent validation of its lead cell therapy candidate, ERNA-101, showing complete tumor clearance and durable survival in ovarian cancer models when combined with anti-PD-1 therapy. This preclinical data, which reproduced earlier findings in a la", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327620/0/en/ernexa-therapeutics-receives-independent-validation-of-erna-101-with-complete-tumor-clearance-and-durable-survival-in-ovarian-cancer-models-ahead-of-planned-clinical-entry.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T12:13:32", "published_display": "15 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Wednesday's Pre-Market Session", "summary": "This article lists several healthcare stocks that are experiencing significant movement in Wednesday's pre-market session. It highlights both gainers, such as Ernexa Therapeutics and Catheter Precision, and losers, including Cardiff Oncology and NextCure, detailing their percenta", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60465595/12-health-care-stocks-moving-wednesday-s-pre-market-session", "source_name": "Benzinga", "published_at": "2026-07-15T12:13:32", "published_display": "15 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics (ERNA) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFBkZ3RVdTlfRXEzbE5ZQ244cEVmR0huaGluWVFaR21pdzl2OFNZQWxUMF92VERMbXJxNlIxaGJVd0ltQXh5VTlJbjJqc2hCUkVnY1B3LXc2cHBqakt1dnBuYk1qYVR4QmRC?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026", "summary": "Ernexa Therapeutics released a new \"CEO Corner\" featuring CEO Sanjeev Luther discussing the company's lead cell therapy candidate, ERNA-101, for advanced ovarian cancer. The video highlights ERNA-101's potential to transform immunologically \"cold\" tumors into those the immune sys", "url": "https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-ceo-corner-highlights-130100722.html", "source_name": "Market source", "published_at": "2026-07-14T13:17:54", "published_display": "14 Jul 2026 13:17", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Preclinical ovarian models: Ernexa's ERNA-101 cleared tumors with PD-1 blockade", "summary": "Ernexa Therapeutics released a CEO Corner video highlighting preclinical data for ERNA-101, its lead therapy candidate for platinum-resistant ovarian cancer. The video showcased complete tumor clearance and 100% long-term survival in ovarian cancer models when ERNA-101 was combin", "url": "https://www.stocktitan.net/news/ERNA/ernexa-therapeutics-ceo-corner-highlights-differentiated-erna-101-y3zud567hg2a.html", "source_name": "Stock Titan", "published_at": "2026-07-14T13:17:54", "published_display": "14 Jul 2026 13:17", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eterna Therapeutics (ERNA) Revenue Breakdown - Main Composition", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T16:33:26+00:00", "published_display": "13 Jul 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eterna Therapeutics (ERNA) News Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygJBVV95cUxPVlZLLVgwQjRPOWlCcExhLXhlT1ZscFVOd19RVHdFS3FJZWpTS2pOaWRBR0pxSlBQLTdsYmVyZFRiMERSMlUtcGRhR0F3MkN6cVNuYTAxSzQ3SnpDWXF2WmFiWEl3dG1EZnl6akk1NkhnckFRNG95WUZLOHZldmRPRHdVbUx1Z2FYRDJNQV9LdU1RU1dUb0FubFAwdTRuWEVPNjh0eDhVeWNOWlZ0WHZtRXZ2RDRId1IxY3lGRGZmNHNEQU1BMWE0dDFhb2lZVnNXd1VySEEzT3hoWU1ZN0ptek9oMGJfejRnZ01QeHJVeDFEalFDZms3aUxuaExyTDZaM29MUnZHbll5ZDdEczZMVXFLMzBWa19GOGF1NEVxaTF5N3MyaWZhaGZLN29DODgwOExHd2hPSzhqa3pXZGRXYl9xS0RfNlVCWEE?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T16:18:24+00:00", "published_display": "13 Jul 2026 16:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eterna Therapeutics(ERNA) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T16:01:27+00:00", "published_display": "13 Jul 2026 16:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eterna Therapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T14:27:07+00:00", "published_display": "13 Jul 2026 14:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Updated July 2026 investor presentation from Ernexa Therapeutics (NASDAQ: ERNA)", "summary": "Ernexa Therapeutics Inc. (NASDAQ: ERNA) has furnished an updated investor presentation for July 2026 as part of a current report on Form 8-K. This updated presentation, which refreshes materials from February 2026, is available as Exhibit 99.1 and on the company's investor relati", "url": "https://www.stocktitan.net/sec-filings/ERNA/8-k-ernexa-therapeutics-inc-reports-material-event-b90adf079c3f.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:12:10", "published_display": "02 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics (ERNA) investors back directors, auditor and 2026 equity plan", "summary": "Ernexa Therapeutics Inc. (ERNA) shareholders approved the election of five directors, ratified Haskell & White LLP as the independent auditor for the 2026 fiscal year, and adopted the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan. These decisions were made at the 20", "url": "https://www.stocktitan.net/sec-filings/ERNA/8-k-ernexa-therapeutics-inc-reports-material-event-711940a5d9b3.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:12:10", "published_display": "02 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Ernexa Therapeutics Inc. \u2013 BOATS:ERNAW", "summary": "The article discusses the price to sales forward metric for Ernexa Therapeutics Inc. (ERNAW). It appears to be a financial data page from TradingView, indicating that the market is closed and no trades have occurred for this specific metric.", "url": "https://www.tradingview.com/symbols/BOATS-ERNAW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:39:33", "published_display": "28 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Ernexa Therapeutics Inc. \u2013 BOATS:ERNAW", "summary": "This article focuses on the \"Price to earnings forward\" metric for Ernexa Therapeutics Inc. (BOATS:ERNAW) as presented on TradingView. It appears to be a financial data snippet rather than a detailed analysis, indicating that there is no current trading activity or value for this", "url": "https://www.tradingview.com/symbols/BOATS-ERNAW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:11:15", "published_display": "28 Jun 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics (ERNA) finance SVP resigns, will aid transition", "summary": "Ernexa Therapeutics Inc. announced the resignation of its Senior Vice President of Finance, Sandra Gurrola, effective July 3, 2026. Her resignation is not due to any disagreements with the company's operations or policies. Ms. Gurrola will provide part-time transition assistance ", "url": "https://www.stocktitan.net/sec-filings/ERNA/8-k-ernexa-therapeutics-inc-reports-material-event-fd208f426337.html", "source_name": "Stock Titan", "published_at": "2026-06-26T22:39:33", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sandra Gurrola to Resign as Ernexa's Senior VP of Finance, Effective July 3, 2026", "summary": "Ernexa Therapeutics announced that Sandra Gurrola, Senior Vice President of Finance, will resign effective July 3, 2026. She will provide limited transition support and her departure is not due to disagreements with the company. Ernexa has initiated a search for her replacement.", "url": "https://www.tradingview.com/news/tradingview:f1926ad3928a9:0-sandra-gurrola-to-resign-as-ernexa-s-senior-vp-of-finance-effective-july-3-2026/", "source_name": "TradingView", "published_at": "2026-06-26T20:33:17", "published_display": "26 Jun 2026 20:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Inc. Announces Resignation of Sandra Gurrola from Senior Vice President of Finance, Effective July 3, 2026", "summary": "Ernexa Therapeutics Inc. announced that Sandra Gurrola, Senior Vice President of Finance, has resigned, with her resignation becoming effective on July 3, 2026. Her departure is not due to any disagreements with the company. Ms. Gurrola will provide part-time transition assistanc", "url": "https://www.marketscreener.com/news/ernexa-therapeutics-inc-announces-resignation-of-sandra-gurrola-from-senior-vice-president-of-finan-ce7f5edadd8cfe22", "source_name": "www.marketscreener.com", "published_at": "2026-06-26T04:30:00", "published_display": "26 Jun 2026 04:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa uses video to explain its cell-therapy strategy and patient mission", "summary": "Ernexa Therapeutics has launched a \"CEO Corner\" video platform featuring CEO Sanjeev Luther to provide deeper insights into the company's progress, scientific strategy, and vision for cell therapies targeting advanced cancer and autoimmune diseases. The inaugural video outlines E", "url": "https://www.stocktitan.net/news/ERNA/ernexa-therapeutics-launches-ceo-corner-to-provide-deeper-insights-uvg0jwk9ersq.html", "source_name": "Stock Titan", "published_at": "2026-06-25T22:10:29", "published_display": "25 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-launches-ceo-corner-131500811.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T13:15:00+00:00", "published_display": "25 Jun 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Launches CEO Corner to Provide Deeper Accessibility", "summary": "Ernexa Therapeutics has launched its new \"CEO Corner\" platform featuring CEO Sanjeev Luther. This initiative aims to provide stakeholders with deeper insights into the company's progress, scientific strategy, and vision for developing innovative, scalable, and affordable cell the", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317625/0/en/ernexa-therapeutics-launches-ceo-corner-to-provide-deeper-insights-into-company-progress-scientific-strategy-and-vision-for-patients.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T13:42:11", "published_display": "25 Jun 2026 13:42", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study", "summary": "Ernexa Therapeutics is on track to become a clinical-stage biotechnology company with its lead oncology candidate, ERNA-101, slated for a Q3 2026 IND submission and a Q4 2026 first-in-human Phase 1 clinical study. The company has made significant progress in manufacturing and reg", "url": "https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-positioned-become-clinical-124700325.html", "source_name": "Market source", "published_at": "2026-06-19T09:09:52", "published_display": "19 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERNA Should I Buy", "summary": "An Intellectia AI analysis suggests that Ernexa Therapeutics Inc (ERNA) is not a strong buy for long-term beginner investors despite a favorable analyst price target of $30. The company shows potential with innovative immune-oncology approaches and clinical trial advancements for", "url": "https://intellectia.ai/en/stock/ERNA/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-06-19T07:11:25", "published_display": "19 Jun 2026 07:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Says Investigational New Drug Submission for ERNA-101 on Track for Q3", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-says-investigational-drug-131905563.html", "source_name": "MT Newswires", "published_at": "2026-06-17T13:19:05+00:00", "published_display": "17 Jun 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa sees ERNA-101 enter first-in-human study in Q4 2026", "summary": "Ernexa Therapeutics (Nasdaq: ERNA) announced significant progress for its lead oncology candidate, ERNA-101, targeting an Investigational New Drug (IND) submission in Q3 2026 and a first-in-human Phase 1 study by Q4 2026. Preclinical data for ERNA-101 combined with PD-1 blockade ", "url": "https://www.stocktitan.net/news/ERNA/ernexa-therapeutics-positioned-to-become-a-clinical-stage-2xaw657p971a.html", "source_name": "Stock Titan", "published_at": "2026-06-17T08:47:00", "published_display": "17 Jun 2026 08:47", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Advances ERNA-101 Towards First-in-Human Trials as Manufacturing and Regulatory Milestones are Achieved | ERNA Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxPVmJBR3JweEhoTHNBUkY4WEJlY1RVOTd0VGNKUUtkQ3hSczJSZHZmVkdhd3VoSnUyb2ZqRHN1bFR6ZUxxUjVLc2hSWTRWaXNkQWVKLTFYNjdIU3k3Qngwb0FJUVlKdzJQc3VJWkFFNG44WVZJQkZMRnRqMTZvdGdnUVRTbzZfWDlveDlHNXRQSHUwMVdxSDlJMlVyWU5NaGxpQ2MwWFZPRktJekhqMnJnaVpxc01yS3FFMmRWQUJ1cFFJTG92VDBYR3k0SVRGVjE3RDlKcG5CVTduMHhWYi1MdzBvOWhOd1gzLUJ2WA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Ernexa Therapeutics Inc. \u2013 NASDAQ:ERNAW", "summary": "This article provides limited information on the number of shareholders for Ernexa Therapeutics Inc. (NASDAQ: ERNAW). It appears to be a stub or a placeholder from TradingView's financial data section, indicating that specific shareholder figures are not immediately presented in ", "url": "https://www.tradingview.com/symbols/NASDAQ-ERNAW/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-12T05:10:28", "published_display": "12 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer", "summary": "Ernexa Therapeutics discussed the significant unmet need in ovarian cancer and the potential of their ERNA-101 program during a Virtual Investor KOL Connect segment featuring Dr. Ira Winer. The discussion highlighted ERNA-101's dual mechanism, off-the-shelf scalability, and poten", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ernexa-therapeutics-highlights-ovarian-cancer-124100377.html", "source_name": "Market source", "published_at": "2026-06-10T03:09:56", "published_display": "10 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need,", "summary": "Ernexa Therapeutics recently participated in a Virtual Investor KOL Connect segment, where Dr. Ira Winer discussed the significant unmet need in ovarian cancer and the challenges of treating immunologically \"cold\" tumors. The discussion highlighted Ernexa's ERNA-101 program and i", "url": "https://www.globenewswire.com/news-release/2026/06/09/3308857/0/en/ernexa-therapeutics-highlights-ovarian-cancer-unmet-need-hope-for-patients-and-potential-accessibility-advantages-of-erna-101-in-virtual-investor-kol-connect-segment-featuring-dr-i.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T08:41:00", "published_display": "09 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ERNA Stock News Today | Earnings, Events & Price Alerts", "summary": "This article provides recent news and events related to ERNA (Ernexa Therapeutics), including updates on its ovarian cancer treatment ERNA-101 and its planned IND submission. Key news highlights involve significant loss narrowing, positive therapy results, and a recent 1-for-25 r", "url": "https://intellectia.ai/en/stock/ERNA/news", "source_name": "Intellectia AI", "published_at": "2026-06-03T09:39:45", "published_display": "03 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa readies ERNA-101 experimental therapy for first human tests, IND Q3 2026", "summary": "Ernexa Therapeutics announced significant progress for its lead therapeutic candidate, ERNA-101, by completing manufacturing milestones including process development and transitioning to GMP manufacturing. These achievements position the company for a planned Investigational New ", "url": "https://www.stocktitan.net/news/ERNA/ernexa-therapeutics-successfully-completes-key-manufacturing-and-ind-ruev4vav4hrx.html", "source_name": "Stock Titan", "published_at": "2026-05-28T09:10:39", "published_display": "28 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ernexa-therapeutics-successfully-completes-key-121100351.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T12:11:00+00:00", "published_display": "27 May 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Stock Is Jumping Today: What's Going On? - Ernexa Therapeutics (NASDAQ:ERNA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQZy1pRDdiSHMxVDBhb0Vfb01NMnFDbHYwT180UmliQUo5Nl9CSmFSU3k3U1lwMzVtR3RodXlFUU40Y2RCc0VVZ0xoR0xENzY3a1VkR2k0bDBvNWtOR0dQSUNCOHFkbVhLa2hla1hIdVJXdklueVVpdmtuN0J5X1lhT3ZKajQ3a1phWHJSLU9FNFByOGNqd0VLY29SOVJJdVc4dEhGZW1YVHA?oc=5", "source_name": "Benzinga", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQV1h5U2QwczdGX2hXRmVKS3FzRTY0ZThRZkRiLXhxWFRsLUZJLU4xY2xfWGk0WjRFUkY3OU5YYW1URDZ4eEpfeXoxS1F3RGhicFZEeVdzczlncjRvUFV2TWhzOFNTRXFWd1ZwQXYxUWY2SWtPUGJCSGpSc2pNNndURDRZamZZMlBCNUZBSTBZSVU0NmhUOExMWkVzSmJOSXpCeXlIaENPUDFQUWhKdG1vNkgtelYzUlVHa1RTQ2Z3?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eterna Therapeutics Reports Promising Preclinical Results for ERNA-101 in Ovarian Cancer Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNRjJYNkt0ak9tUXNqT181S1dLRlFzbU5qR1YtZGdPdHhsSVNZQnZWTGdVOFJhUXNVWnhsN2RUSE53VTBMbXo1azBrUlVBajhQNExySV9SMDAyUXdGd1RCSmJ2QWZPcmF3ZTJzX0lvWkZ6QTFoUVFOalNvZzdVZ0lybWJKcldWZVpiRjhZMnV5aTBQeWlkTm95MzA5OWZkU0M4U1FITlpWN1RYUXJFdU9xWlNrNTBJTHlyQmRRZnRwTXF4LVdxY09zUTRrQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-01-14T08:00:00+00:00", "published_display": "14 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ernexa Therapeutics (ERNA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5OQmc0V1paTHdReEFvVFpGdDlCVXJoSTl2MkQ0V0tuakNTX3BmazBqdXlQMDU1VVlsMVlSUkczVE82aTlWSEJpbmZHX1NXenp0WjktWUR6WGVYQQ?oc=5", "source_name": "MarketBeat", "published_at": "2022-10-20T11:01:36+00:00", "published_display": "20 Oct 2022 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 51, "sentiment_summary": {"positive": 17, "negative": 2, "neutral": 32, "score": 59, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 6.42, "latest_week": "2026-07-17", "one_week_move": 5.9, "four_week_move": 3.5, "twelve_week_move": 34.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.62936, "market_dynamics_buy_signal": false, "relative_strength": -74.501158, "fair_value_gap": -98.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 37.6285, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.9% over one week, +3.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 70, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "Quiver Quantitative", "count": 3}, {"label": "MT Newswires", "count": 2}, {"label": "Benzinga", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 14}, {"label": "Regulatory and legal", "count": 4}, {"label": "Guidance", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.9% over one week, +3.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Ernexa Therapeutics announces 1-for-25 reverse stock split; shares down"}], "updated_at": "2026-07-22T04:55:21.782519+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}